An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

Author： Ray Joshua A.   Carr Emma   Lewis Gavin   Marcus Robert  

Publisher： Blackwell Publishing

ISSN： 1098-3015

Source： Value in Health, Vol.13, Iss.4, 2010-06, pp. : 346-357

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada

By Johnston Karissa M.   Marra Carlo A.   Connors Joseph M.   Najafzadeh Mehdi   Sehn Laurie   Peacock Stuart J.  

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 703-711

Blackwell Publishing

Access to resources Recommend Favorite

Cost Effectiveness of Rituximab for Non-Hodgkin's Lymphoma: A Systematic Review

By Auweiler Philipp W.P.  

PharmacoEconomics, Vol. 30, Iss. 7, 2012-07 ,pp. : 537-549

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin's Lymphoma

By Fagnoni Philippe   Milpied Noel  

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 55-68

Adis International

Access to resources Recommend Favorite

Rituximab added to CHOP chemotherapy shows promise as a treatment for HIV-associated non-Hodgkin's lymphoma (NHL)

By  

Inpharma, Vol. 1, Iss. 1551, 2006-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma

By Jamal-Hanjani Mariam   Pettengell Ruth  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1441-1448

Informa Healthcare

Access to resources Recommend Favorite